Results 251 to 260 of about 6,606,497 (285)
Some of the next articles are maybe not open access.
Post-marketing surveillance of quinolones 1988–1990
European Journal of Clinical Microbiology and Infectious Diseases, 1991It has been much easier to obtain original data on adverse drug reactions (ADR) of quinolones from the pharmaceutical industry than it was two years ago. This is to be welcomed and, as anticipated, the new data continue to suggest that the new 4-quinolones have an ADR profile which is very similar to that of other antimicrobials.
P G, Davey, T, McDonald, G, Lindsay
openaire +2 more sources
Post-marketing drug surveillance
1981It is regrettable that the term ‘Post-marketing Surveillance’ (PMS) has become synonymous in many minds with certain types of prescription-based monitoring, proposed during the last 5 years1–5, to the exclusion of other methods that have been in effective use for many years.
W. H. W. Inman, C. T. Dollery
openaire +1 more source
Post-Marketing Surveillance of Psychotropic Drugs
1989At the end of a highly sophisticated scientific programme, the author has the honour as well as the difficulty to consider more generally the field of post-marketing surveillance of psychotropic drugs. Although post-marketing surveillance has gained considerable attention in recent years, little has been published about post-marketing surveillance of ...
openaire +2 more sources
Survey Method for Post-Marketing Drug Surveillance
Journal of Clinical Psychopharmacology, 1988Distinguishing characteristics of a community survey method for post-marketing drug monitoring are described, as are results of a pilot study of the method. Representative samples of outpatients treated with tricyclic antidepressants or benzodiazepine anxiolytics were identified in a clinic or pharmacy and interviewed at baseline and specified ...
G D, Mellinger +4 more
openaire +2 more sources
[Post-marketing surveillance studies].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005Approval of a drug on the market is typically considered as the successful endpoint of a long development phase. This often leads to reduced interest in further research for the indication approved, while in contrast the patient's as well as physician's interest in further research increases. This paper discusses the main areas of effectiveness, safety
I, Pigeot, J, Windeler
openaire +1 more source
post-marketing surveillance (PMS)
2009syn. drug monitoring, pharmacoepidemiology involves the collection of clinical data on marketed medicines, primarily on drug safety (incidence of esp. rare side effects, new hazards, specific risk factors, risk/benefit analysis) but also on unexpected benefits, and their scientific evaluation or cost/benefit aspects, and to evaluate if drugs are ...
openaire +1 more source
Post‐marketing surveillance of drugs
Medical Journal of Australia, 1991H Peter Roeser, Alain P Rohan
openaire +2 more sources
Post-marketing device safety surveillance
Contemporary Clinical Trials, 2011Venkatesan D, Vidi +2 more
openaire +2 more sources
Post marketing surveillance for implants
International Journal of Risk and Safety in Medicine, 1996openaire +3 more sources